Once-weekly prophylaxis regimen of nonacog alfa in patients with hemophilia B: an analysis of timing of bleeding event onset

Basit Öğe Kaydı
dc.contributor.authorTortella B.J.
dc.contributor.authorCarr M.E.
dc.contributor.authorRendo P.
dc.contributor.authorKorth-Bradley J.
dc.contributor.authorSmith L.M.
dc.contributor.authorKavakli K.
dc.date.accessioned2021-05-03T20:56:58Z
dc.date.available2021-05-03T20:56:58Z
dc.date.issued2021
dc.description.abstractIn a pivotal, multicenter, open-label study, 25 patients aged 12-54?years with moderately severe/severe hemophilia B received on-demand nonacog alfa (6?months; dose at investigator's discretion) followed by once-weekly prophylaxis with nonacog alfa 100?IU/kg (12?months). During prophylaxis, patients had a median spontaneous annualized bleeding rate (sABR) of 1.0 and significant reductions in ABR (P?<?0.0001). This post hoc analysis examined the time of onset of spontaneous bleeding events (sBEs) and spontaneous target joint bleeding events (sTJBEs). The postdosing day (D) of onset of sBEs observed during prophylaxis and steady-state FIX activity data (FIX:C) between 144 and 196?h postdose were collected at weeks 26 and 78. Twelve patients (48%) had no sBEs; the remaining 13 (52%) had the following onset of sBEs: less than 1 D (0%), 1 to less than 2D (5%), 2 to less than 3 D (22%), 3 to less than 4 D (9%), 4 to less than 5D (22%), 5 to less than 6D (23%), 6 to less than 7D (11%), and at least 7D (8%). Reductions in sBEs and sTJBEs during on-demand versus prophylaxis treatment were experienced by all 13 patients. Target joint sABR during prophylaxis was 0 for 5/13 patients. ABR reduction ranged from 66.1% (27.2?9.2) to 97.8% (46.2?1.0); sTJBE reductions ranged from 6.2% (2.1?2.0) to 100% (from 40.1, 19.1, 3.9, 9.0, 6.1--0). During prophylaxis, 47% (8/17) of trough FIX activity samples were more than 2%. In sBE patients, ABR and number of TJBEs were reduced with once-weekly nonacog alfa. When sBEs occurred, they followed no apparent pattern for day of occurrence. Clinicaltrials.gov identifier: NCT01335061. Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.en_US
dc.identifier.doi10.1097/MBC.0000000000001012en_US
dc.identifier.endpage185en_US
dc.identifier.issn1473-5733
dc.identifier.issue3en_US
dc.identifier.pmid33631774en_US
dc.identifier.scopus2-s2.0-85104046640en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage180en_US
dc.identifier.urihttps://doi.org/10.1097/MBC.0000000000001012
dc.identifier.urihttps://hdl.handle.net/11454/71441
dc.identifier.volume32en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherNLM (Medline)en_US
dc.relation.ispartofBlood coagulation & fibrinolysis : an international journal in haemostasis and thrombosisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleOnce-weekly prophylaxis regimen of nonacog alfa in patients with hemophilia B: an analysis of timing of bleeding event onseten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu